期刊文献+

结直肠癌肝转移转化化疗的现状与展望

Current status and future perspectives on Conversion therapy of liver metastasis in colorectal cancer
原文传递
导出
摘要 结直肠癌实质性器官转移中最常见的部位是肝脏,在诊疗过程中超过一半的结直肠癌患者都会发生肝转移。结直肠癌是否发生肝转移极大的影响了临床决策并直接决定了患者的预后。尽管化疗、手术的生存率有所提高,但将肝转移灶完整的切除是结直肠癌肝转移患者获得潜在治愈的唯一机会,多数证据表明外科手术具有显著的生存效益。转移灶肝切除术后的5年生存率可达到35%~55%。遗憾的是,只有10%~20%的患者被认为有资格进行手术切除。因此,运用转化治疗将初始不可切除的CRLM转化为可切除CRLM,从而提高m CRC患者的手术切除率、延长生存时期和改善预后,是当前的研究热点。本文就转化治疗(conversion therapy)中转化化疗的内涵、转化方法、研究进展进行综述。 Liver metastasis is the most common site of colorectal cancer metastasis. More than half of all colorectal cancer patients will develop liver metastases. Whether colorectal cancer has liver metastasis has great impact on clinical decisionmaking and directly determines the prognosis of patients. Although radical surgery is the standard treatment modality,only10 ~ 20% of patients are deemed eligible for resection. Despite advances in survival with chemotherapy,surgical resection is still considered the only curative option for patients with liver metastases. The majority of evidence stated a significant survival benefit with surgical resection to reach an overall 5-year survival rate of 35% ~ 55% after hepatic resection. thus improving the surgical resection rate,prolonging the survival time and improving the prognosis of m CRC patients. In this review,we describe the connotation,transformation methods and research progress of conversion chemotherapy in conversion therapy.
作者 乔鋆 张睿 Yun Qiao;Rui Zhang(Department of Colorectal Surgery, Cancer Hospital of China Medical University/Liaoning Cancer Hospita)
出处 《辽宁医学杂志》 2018年第3期11-14,共4页 Medical Journal of Liaoning
关键词 转化治疗 靶向药物 联合化疗 二线转化 Conversion therapy Targeted drugs Combination chemotherapy Second line conversion
  • 相关文献

参考文献1

二级参考文献1

  • 1Janja Ocvirk,Thomas Brodowicz,Fritz Wrba,Tudor E Ciuleanu,Galina Kurteva,Semir Beslija,Ivan Koza,Zsuzsanna Pápai,Diethelm Messinger,Ugur Yilmaz,Zsolt Faluhelyi,Suayib Yalcin,Demetris Papamichael,Miklós Wenczl,Zrinka Mrsic-Krmpotic,Einat Shacham-Shmueli,Damir Vrbanec,Regina Esser,Werner Scheithauer,Christoph C Zie-linski.Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial[J].World Journal of Gastroenterology,2010,16(25):3133-3143. 被引量:17

共引文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部